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Epstein-Barr virus (EBV) is a well-known carcinogenic virus, and the association of EBV with 
some tumours suggests that there may also be an association between laryngeal carcinoma and EBV.
Objective: The aim of this study is to determine the role of EBV in the aetiology of laryngeal car-
cinoma.
Method: Prospective investigation the EBV with real time polymerase chain reaction in tumour 
tissues of 25 patients with laryngeal carcinoma and 17 patients with benign laryngeal lesions, and 
investigation of the relationship between the presence of viral DNA and patients’ smoking habits, 
alcohol consumption, localization and differentiation of the tumour.
Results: There was no significant difference between the control group and patient group in terms 
of EBV polymerase chain reaction positivity (p > 0.05). Also we couldn’t find a statistically significant 
relationship between EBV positivity and differentiation of the tumour, localization of the tumour, 
smoking and alcohol consumption habits (p > 0.05).
Conclusion: Our results suggest that, although EBV is present in some of the squamous cell laryngeal 
carcinomas, its presence has no effect on the pathogenesis of laryngeal carcinomas.
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INTRODUCTION
Head and neck malignancies accounts for 4% of 
all types of cancers, and laryngeal carcinoma accounts 
for 25% to 40% of head and neck malignancies1. The role 
of many factors, especially tobacco use and alcohol con-
sumption, has been clearly shown in the development of 
laryngeal carcinoma. Also it is known that certain viruses 
have oncogenic potentials, and the relationship between 
laryngeal carcinoma and viruses has been a popular subject 
of research for many years2-4.
Epstein-Barr virus (EBV) is present in all popula-
tions, infecting more than 95% of human beings within 
the first decade of life5. The host range of the Lympho-
cryptovirus genus, which also includes EBV, is generally 
restricted to primate B lymphocytes, which are also the 
site of latent virus infection in vivo. Infection of primate 
B-lymphocytes with lymphocryptoviruses typically results 
in a latent infection characterized by persistence of the 
viral genome with expression of latent gene products that 
contribute to the transformation process and cell prolife-
ration6. The close relationship between EBV infection and 
nasopharyngeal carcinoma has been widely accepted7. 
Carcinomas that share the histological features of undiffe-
rentiated nasopharyngeal carcinomas have been identified 
in other sites of body, including the thymus, larynx, tonsils, 
salivary glands, lungs, skin, uterine cervix, bladder, and 
stomach2,7-23. Recently, studies have reported polymerase 
chain reaction detection of EBV in a significant percentage 
of breast and hepatocellular carcinomas5,7,8,23. Also some 
studies showed a possible role of EBV in the development 
of squamous cell laryngeal carcinoma8.
Objective
We investigated the DNA of the EBV with a sensi-
tive and specific molecular method, real time polymerase 
chain reaction (RT-PCR), in tumour tissues of patients 
with laryngeal carcinoma to determine the role of EBV in 
the aetiology of laryngeal carcinoma. We also analyzed 
the relationship between the presence of viral DNA and 
patients’ smoking habits, alcohol consumption, localization 
(glottic, supraglottic or subglottic) and differentiation of 
the tumour (well, moderate, poor).
METHOD
Samples taken from fresh tumour tissues of ran-
domly selected 25 patients that attended to the Depart-
ment of Otolaryngology-Head and Neck Surgery between 
November 2007 and November 2008 with complaints of 
hoarseness, dyspnea, cough, sore throat and diagnosed as 
laryngeal carcinoma based on pathology results following 
laryngectomy or biopsy were included to the study.
Control group was composed of fresh tissue 
samples taken from patients that operated for benign 
laryngeal lesions like laryngeal polyps, nodules, cysts 
or granulomas. Also, biopsies taken from patients with 
diagnosis of laryngeal cancer that subsequently revealed 
to be a benign lesion after pathologic examination were 
included to the control group. A total of 17 samples 
obtained from patients with benign lesions consisted the 
control group. Biopsies taken from premalignant lesions 
like leukoplakia or dysplasia were not included to the 
study. The study was done with the approval of ethics 
committee of the institution. (approval nº 09-230). Every 
patient was informed about the study preoperatively and 
a signed consent was taken.
All samples were taken in operation room from fresh 
tissue biopsies just before formalin fixation of the tissue, 
in a sterile manner to avoid contamination risk.
Patients underwent thorough head and neck exa-
mination including indirect laryngoscopic evaluation and 
they were assessed in terms of localization of the tumour, 
smoking and alcohol consumption habits, duration of 
smoking and alcohol consumption and histopathological 
type of the tumour. Data for smoking and alcohol con-
sumption habits were collected preoperatively with the 
help of a specific questionnaire that included questions 
about the duration and amount of consumption. Necessary 
imaging studies were done in patients suspected to have 
cancer before direct laryngoscopic biopsy.
Presence of EBV DNA in tissue samples was investi-
gated by quantitative PCR using RT-PCR technique.
Obtaining DNA
EBV DNAs were obtained from the samples using 
QIA amp DNA minikit (Qiagen, Germany) in accordance 
with the user manual of the kit.
Multiplication of DNA
DNAs obtained from tissue samples were multiplied 
with Rotor-Gene 6000 (Corbett research, Australia) device 
using Qiagen Artus EBV RT PCR kit (Catalog Number 
4501263) (Lot Number 130162115) (Sensitivity 3.8 copy/
µl). In every study, one negative control was used to avoid 
contamination risk.
Evaluation of Data
Data analyses were performed using Software ver-
sion Rotor-Gene 1.7.75. EBV quantitation kit included 2 
fluorescent dyes, JOE and FAM. While JOE ensures visible 
internal control, FAM indicates EBV DNA positivity. JOE 
is checked in yellow channel at a wavelength of 530-555 
and FAM is checked in green channel at a wavelength of 
470-510.
Results were interpreted as:
1. If FAM channel is positive: EBV DNA is positive 
in the sample. If positivity is very high, JOE 
channel may be negative;
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2. If FAM channel is negative and JOE channel is 
positive, EBV DNA is negative in the sample. If 
JOE channel is negative too, the reaction was 
thought to be inhibited by an inhibitor and thus 
analysis was repeated.
Statistical analysis
The Chi-square test was used to compare the 
EBV PCR positivity of the study and control groups and 
to determine the association of EBV PCR positivity and 
patients’ smoking habits, alcohol consumption, localiza-
tion of the tumour (glottic, supraglottic, subglottic) and 
differentiation of tumour tissue (well, moderately, poorly). 
All statistical calculations were performed using commer-
cially available software (SPSS version 15.0 for Windows; 
SPSS Inc, Chicago, Illinois) and p < 0.05 was considered 
to be significant.
RESULTS
Samples taken from 25 male patients (aged between 
42 to 67 years, with a mean of 54.6) that attended to 
Otorhinolaryngology clinic and diagnosed as laryngeal 
carcinoma after direct laryngoscopic biopsy were included 
to the study. Samples were taken during partial or total 
laryngectomy in 13 patients and during laryngoscopic 
biopsy in 12 patients. Control group was composed of 
tissue samples taken from 17 patients (mean age 48.8, 13 
males (76.5%) and four females (23.5%)) that had attended 
to clinic with hoarseness and found to have a benign 
laryngeal lesion (eg. laryngeal polyp, granuloma, cyst) after 
laryngoscopic examination and biopsy results. After head 
and neck examinations and direct laryngoscopy, patients 
that had laryngeal carcinoma were divided into 3 groups as 
glottic, supraglottic and subglottic based on the localization 
of the tumour. The tumour was glottic in 64% (16/25) of 
the patients, while supraglottic laryngeal carcinoma was 
detected in 36% (9/25) of them. No subglottic lesion was 
detected in our study group.
Tissue samples taken from the patients were studied 
by quantitative PCR using RT-PCR technique for detection 
of EBV DNA. Internal control was found to be positive in 
all of the patients.
EBV PCR positivity was found in 40% (10/25) of the 
laryngeal carcinoma patients. EBV DNA was £103 copy/ml 
in three patients, 103-105 copy/ml in six patients and 105 
copy/ml in one patient. It was positive in 66.7% (6/9) of 
the supraglottic tumours and in 25% (4/16) of the glottic 
tumours. In the control group, 52.9% (9/17) of the patients 
were EBV PCR negative while the remaining 47.1% (8/17) 
were EBV PCR positive. In five of these patients, EBV DNA 
was £103 copy/ml, and in the remaining three, EBV DNA 
was 103-105 copy/ml. There was no significant difference 
between the control group and patient group in terms of 
EBV PCR positivity, and no direct correlation was found 
between EBV and the pathogenesis of laryngeal squamous 
cell carcinoma (SCC) (p > 0.05) (Table 1). Also, there was 
no significant relationship between EBV DNA positivity 
and localization of the tumour (p > 0.05).
Table 1. EBV positivity rates of the patients and control group 
and the association between EBV positivity, localization and 
differentiation of the tumour.
EBV negative EBV positive p
Cancer patients (N: 25) 15 (60%) 10 (40%)
0.892
Control group (N: 17) 9 (52.9%) 8 (47.1%)
Localization 
of the tumour
Glottic 12 (75%) 4 (25%)
0.087
Supraglottic 3 (33.3%) 9 (66.7%)
Differentiation 
of the tumour
Poorly 
differentiated 2 (40%) 3 (60%)
0.328
Moderately 
differentiated 5 (62.5%) 3 (37.5%)
Well 
differentiated 8 (72.7%) 3 (27.3%)
Basaloid type 0 (0%) 1 (100%)
Pathologic investigation of the samples taken from 
the patients revealed that, 44% (11/25) of the patients 
had well differentiated SCC, 32% (8/25) had moderately 
differentiated SCC, 20% (5/25) had poorly differentiated 
SCC and 4% (1/25) had basaloid type SCC. EBV DNA 
positivity was found in 27.3% (3/11) of the patients that 
had well differentiated SCC, in 37.5% (3/8) of the patients 
that had moderately differentiated SCC, in 60% (3/5) of 
the patients that had poorly differentiated SCC and it was 
also positive in the only patient that had basaloid type 
SCC (Table 1). We could not find a statistically significant 
relationship between EBV positivity and differentiation of 
the tumour (p > 0.05).
Patients that have cancer and controls were in-
terviewed for determination of smoking and alcohol 
consumption habits. 96% (24/25) of the patients in the 
laryngeal carcinoma group were smokers while there was 
only one patient who was a non-smoker. Smoking period 
ranged from 15 to 43 years (mean 30 ± 4.5 years) with 20 
to 40 cigarettes daily (mean 24.5 ± 8.25 cigarettes). Sixty 
percent (15/25) of the patients were drinking alcohol on 
regular basis (at least twice a week) for a duration of 10 
to 30 years (mean duration of alcohol consumption was 
22.5 years). In the control group, 76.5% (13/17) of the 
patients were smokers. Smoking period ranged from 14 to 
39 years (mean 27.3 ± 3.8 years) with 20 to 40 cigarettes 
daily (mean 23.5 ± 7.5 cigarettes). Of these patients, 17.6% 
(3/17) were found to consume alcohol regularly and the 
mean duration of alcohol consumption was 28.3 years 
(20 to 35 years). EBV DNA positivity was 37.5% (9/24) 
in tissue samples of smoking cancer patients. In control 
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group, EBV DNA positivity was found to be 46.2% (6/13) in 
smokers. In cancer group, samples taken from the patients 
that consume alcohol revealed an EBV DNA positivity of 
40% (6/15). EBV DNA was not found in samples taken 
from control patients that consume alcohol. There was 
no statistically significant association between EBV DNA 
positivity and smoking and alcohol consumption habits 
(p > 0.05) (Table 2).
been shown in samples taken from laryngeal carcinoma 
patients in some studies, HPV has not been considered 
to have a strong carcinogenic effect in development of 
laryngeal carcinomas because these observations were 
exceptional28,29. Recently, there have been some reports 
presenting the association of EBV with laryngeal carci-
noma8, and a number of reports refuting these data19,30.
Gök et al.20 investigated the presence of EBV DNA 
in formalin-fixed, paraffin-embedded tissue samples 
from 22 patients with squamous cell carcinoma of the 
larynx and from 17 patients with vocal cord nodules by 
PCR. Polymerase chain reaction showed EBV DNA in 11 
patients (50%) with laryngeal carcinoma and in seven 
patients (41.2%) with vocal cord nodules. They could not 
find any significant difference between groups in terms of 
EBV DNA positivity and duration of smoking, the number 
of cigarettes consumed daily, localization of the disease 
and tumour stage, which are consistent with our results.
Goldenberg et al.21 also could not find any signifi-
cant relationship between EBV and tumour development in 
the study they performed on three hundred patients with 
head and neck cancer, including larynx, hypopharynx, 
oropharynx and oral cavity tumours21. They also could 
not find any correlation between EBV positivity and to-
bacco exposure, alcohol consumption or tumour grade. 
They found low quantities of EBV detected in a minority 
of head and neck cancers and they connected this to the 
presence of EBV genome in rare lymphoid or epithelial 
cells adjacent to the primary head and neck cancer.
In the study of de Oliveira et al.2, EBV was studied 
with molecular biological techniques in parafinnized tu-
mour tissues taken from 110 patients having squamous cell 
laryngeal carcinoma, and EBV was detected in none of the 
patients. Similarly, Atula et al.19 suggested that EBV was not 
associated with laryngeal carcinoma after they analyzed 
EBV DNA in 79 frozen biopsy samples of head and neck 
cancer patients with Southern blot hybridization and PCR.
In their study, Vlachtsis et al.22 demonstrated EBV 
DNA positivity in 39 (43.3%) of 90 laryngeal SCC patients 
while both HPV and EBV positivity was found in 19 (21.1%) 
of them. It is impossible to determine the effect of EBV on 
laryngeal carcinoma regarding to their results because they 
did not have a control group, but their EBV DNA positiv-
ity rate in laryngeal SCC was similar to what we found.
Kiaris et al.8 have also studied the incidence of EBV 
in SCC of larynx. They analyzed EBV DNA presence by 
sensitive PCR and used RFLP (restriction fragment length 
polymorphism) for further confirmation of the specificity 
of the PCR-amplification reaction. EBV DNA was posi-
tive in 9 of the 27 tumour tissues while only four (15%) 
specimens from adjacent normal tissue exhibited evidence 
of EBV infection. Three samples were EBV positive for 
both normal and tumour tissue. Researchers have found 
a relatively high incidence of EBV in the tumour tissue 
Table 2. Tobacco and alcohol consumption characteristics and 
EBV positivity rates of the patients.
Cigarette EBV negative EBV positive p
Control group 
(N: 17)
(-) 2 (50%) 2 (50%)
1.000
(+) 7 (53.8%) 6 (46.2%)
Cancer patients 
(N: 25)
(-) 0 (0%) 1 (100%)
0.400
(+) 15 (62.5%) 9 (37.5%)
 Alcohol EBV negative EBV positive p
Control group 
(N: 17)
(-) 6 (42.9%) 8 (57.1%)
0.206
(+) 3 (100%) 0 (0%)
Cancer patients 
(N: 25)
(-) 6 (60%) 4 (40%)
1.000
(+) 9 (60%) 6 (40%)
DISCUSSION
EBV is present in all populations, infecting more 
than 95% of human beings within the first decades of life7. 
In developing countries, certain cultural practices often 
lead to EBV exposure in early childhood, and primary 
EBV infection in young children is typically associated 
with an unremarkable acute syndrome. In more devel-
oped countries, however, infection is often delayed, and 
acute primary EBV infection occurring in adolescence or 
adulthood can result in a self-limiting lymphoproliferative 
disorder known as infectious mononucleosis (IM)6.
Data from several studies suggests that EBV is 
involved in the development or progression of squamous 
cell carcinoma of the nasopharynx, oral cavity, larynx and 
esophagus, as well as in gastric epithelioma and Hodgkin’s 
lymphoma8-16,23-25. In addition, it has also been implicated 
in the etiologies of the African type Burkitt’s lymphoma, 
thymic carcinoma and Sjögren’s syndrome17,19.
The strongest environmental factor in the pathogen-
esis of laryngeal carcinoma is smoking. Gastroesophageal 
reflux, radiation, consuming fruits and vegetables which 
are rich in carotenoids and exposure to wood dust, heavy 
metals and coal dust are among suspected etiological fac-
tors26. Additionally, it has been thought that viral factors 
could play a role in the etiology of laryngeal carcinoma too. 
Some studies, with different results, have been conducted 
on the role of viral factors, mainly investigating the effects 
of Human Papillomavirus (HPV) and EBV in the etiology 
of laryngeal carcinoma27. Although various HPV types have 
422
Brazilian Journal of otorhinolaryngology 79 (4) July/august 2013
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
(33%) of patients with laryngeal cancer, as compared to 
the low incidence (15%) of the virus genome detected in 
the adjacent normal tissue, which indicates a probable role 
of EBV in the development of the disease. However, they 
found no association with EBV positivity and stage of the 
disease and histological differentiation.
In our study, we could not find a significant rela-
tionship between the control group and patient group in 
terms of EBV PCR positivity and viral load of EBV. Similarly 
there was no direct association between EBV and patho-
genesis of laryngeal squamous cell carcinoma. Most of 
the studies that performed previously support our results, 
but there are few studies that demonstrate an association 
between EBV and laryngeal SCC. We believe that such 
contradictory results are due to the small sample size and 
variety in sensitivity and specificity of the methods used 
for determination of EBV.
We also could not find a significant association 
between EBV positivity and localization and differentia-
tion of the tumour (p > 0.05). Furthermore, since smoking 
and alcohol consumption are well-established risk factors 
for development of laryngeal carcinoma, we investigated 
the association between EBV positivity and these factors, 
and we could not demonstrate any relationship between 
smoking and alcohol consumption habits and both EBV 
positivity and viral load (p > 0.05). These results suggest 
that EBV does not play a synergistic role in development 
of laryngeal carcinomas with irritative factors like smoke 
and alcohol.
The main advantage of our study was the usage of 
fresh tissue samples for the determination of EBV DNA. 
Most of the previous studies investigating presence of EBV 
were performed on samples taken from formalin fixed, 
paraffin embedded tissues and formalin is a known inhibi-
tor for PCR31. Hence, some false negative results could have 
been obtained in some of the previous studies.
In this study, surgical specimens of patients with 
benign laryngeal lesions were accepted as controls since 
taking tissue samples from healthy volunteers was not 
reasonable. Interestingly, EBV DNA was found to be 
positive in 47.1% of patients in this group, and this ratio 
was higher than the study group. So, it can be suggested 
that EBV is a very common virus that could stay latent in 
mucosal cells of the upper airway in considerable propor-
tion of the population.
CONCLUSION
Recently established association of EBV especially 
with the non-differentiated nasopharyngeal carcinoma 
has let to the consideration that there may also be an 
association between laryngeal carcinoma and EBV. But our 
results, in concordance with the results of the majority of 
the previous studies, suggest that, EBV is a very common 
virus that can be found in the mucosal cells of the upper 
airway in considerable proportion of the population, and 
although EBV is present in cancer tissues of some of the 
squamous cell laryngeal carcinomas, its presence has no 
effect on the pathogenesis of laryngeal carcinomas. Further 
multicentric studies with large sample sizes have to be 
performed to demonstrate the relationship between EBV 
and squamous cell laryngeal carcinoma clearly. By this 
way, with any possible association that could be found, 
positive steps can be taken in terms of prevention and 
management of laryngeal carcinomas.
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